drugset
drugset / Trial / NCT05023811

A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects

NCT05023811 ↗

Phase 1 Completed 6 enrolled Aristea Therapeutics, Inc.
NaSingle-groupOpen-labelOther

Summary

A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of \[14C\]RIST4721 Following a Single Oral Dose to Healthy Male Subjects

Timeline

Start
2021-08-11
Primary completion
2021-09-15
Completion
2021-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject RIST4271 Unknown — Oral

Indications

No indication recorded.